



CUPID LIMITED

Manufacturer & Exporter of Male Condoms, Female Condoms,
Water based Lubricants & In Vitro Diagnostics (IVD) Kits

We Help The World Play Safe

Date: 7th August, 2024

To,
Department of Corporate Services,
BSE LIMITED,
Phiroze Jeejeebhoy Towers,
Dalai Street,
Mumbai -400 001
SCRIP CODE: 530843

The National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor, Bandra-Kurla
Complex, Bandra (East),
Mumbai - 400051
Fax No.-6641 8125/26
SCRIP CODE: CUPID

Subject: - Q1FY2025 Investor Presentation

Dear Sir / Madam,

With reference to the captioned subject attached herewith the Q1FY2025 Investor Presentation for your reference.

Kindly take the same on your records.

For Cupid Limited

SAURABH VISHWAS KARMASE
Digitally signed by
SAURABH VISHWAS
KARMASE
Date: 2024.08.07
17:14:42 +05'30'

Saurabh V. Karmase
Company Secretary and Compliance Officer

Factory & Registered Office:

CIN No.: L25193MH1993PLC070846



A-68, M.I.D.C. (Malegaon), Sinnar,
Nashik - 422113, Maharashtra, India



+91 2551 230280 / 230772
+91 7722009580



www.cupidlimited.com
info@cupidlimited.com

Cupid Ltd.

NSE: CUPID:BSE: 530843

Q1 FY25 Investor Update









Key Operational Highlights

- ↗ The board has approved the incorporation of a wholly owned subsidiary in UAE to capture market share in the GCC region
- ↗ The design of the green field plant at Palava is ready, the plant should be operational by the end of calendar year 2025
- ↗ IVD business has become PAT positive
- ↗ Pocket Perfumes and Deodorants launched for B2C business with Perfume Products, Hair Oils, Massage Oils and Creams under development
- ↗ Notable hiring in the B2B Export Team
- ↗ Company has successfully started implementation of the SAP S4HANA ERP System
- ↗ Company has made notable progress in CE Mark and WHO Prequalification Certification processes for its 5 best-selling IVD tests
- ↗ US FDA Approval process has been renewed and is underway for the Cupid Version 3 Female Condom



Financial Highlights

(₹ in Lakhs)



Revenue Growth for Q1FY25

Segment-wise Revenue

Particulars	Q1FY25	Q1FY24
Male and Female contraceptives & Jelly	89.75%	99.55%
IVDs	4.06%	0.45%
New Products	6.19%	-

Geographic Revenue Split

Particulars	Q1FY25	Q1FY24
Domestic	48%	5%
Export	52%	95%

Forward-Looking Statements

↗ Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local political or economic developments, technological risks, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward looking statements. Cupid Limited will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.





Thank You

For further information

Bosky Christopher, Account Director, Intellect IR

M: 9820038229

E-mail: bosky@intellectpr.com